The C.H.I.E.F.S. Story – Your Dilemma

Since Donald Trump signed the Executive Order on the evening of Saturday, February 1, 2025, authorizing a 25% tariff on all Canadian made goods, you are now faced with a dilemma that is likely keeping you up at night.

Specifically, the US is the only fully private market in the world for health innovations and now you are questioning, after all you’ve poured into it, if this is even a viable option for your innovation.

Even if somehow we eliminate the draconian measures in the Canada Free Trade Agreement (CFTA) that restricts your ability in your own country, this is still an extremely small market. Add to that the cost of entering the European, Asian, Pacific Rim, or even the LATAM markets, they too aren’t fully private and is your IP even covered? Plus, they’d add another regulatory burden you were probably planning to address after FDA (and Health Canada approvals). Moreover, their reimbursement levels are a fraction of the U.S.

So now you know you have to move forward, but how?

Enter the C.H.I.E.F.S. Tool?.

The overall fundamentals, except for a possible 25% increase at the cost of goods level, haven’t changed. And, where your company aligns is clearly delineated in the results shown in the C.H.I.E.F.S. Tool?. For the C$1,000 (plus HST) within days you have an immediate reading on where you stack up. Add the automatic six month re-examination, at no additional cost, for both a trend line AND valuable data for due diligence and even marketing guidance.

For those of you who joined my webinar last month, hosted by OBIO, I treated the audience to a Test Case of the full C.H.I.E.F.S. program. As you will have seen I used data from a real Canadian innovator, who initially had a 12/50 result. After six months, this was significantly improved to 20/50 (+66%). However, that was still below the top score of 23/50 by a Canadian innovator and far below the minimum of 27/50 for an American at effectively the same level of development.

I also shared the six month accomplishments that were primarily funded by receiving their SR&ED (Scientific Research and Experimental Development) tax credit..

Additionally, I provided two lists for “Addressing the New Challenge.” One flagged the “Easy Stuff” like,

A.??? 1) Get a US address (e.g. mailbox at the UPS Store)

B.??? 2) Shared office space & services (e.g. Regus)

C.???? 3) Network extensively at US conferences

D.??? 4) Join the local CEO/Leadership association

E.???? 5) Set up US banking through your Canadian affiliate

The other covered the “Harder Stuff” including,

·????? Determine the business structure (LLC or S or C–corp.)

·????? Optimize share structure to avoid double taxation

·????? Engage Global Affairs for determining best locale

·????? Enroll with the local SBDC for small business support

·????? Lobby elected officials at ALL levels

·????? Partner with a distributor

Although the Test Case also included the optional C.H.I.E.F.S. Outcomes?, today’s focus is C.H.I.E.F.S. Tool? and how it should be an imperative if you truly want to overcome your critical dilemma.

?

?